BioSpace News Archive

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced changes to the Company’s Executive Leadership Team.

Bristol Myers Squibb Company announced that Elizabeth Mily has been appointed Executive Vice President, Strategy & Business Development, effective March 30, 2020.

EUSA Pharma announced the initiation of the Papa Giovanni XXIII Hospital sponsored study of siltuximab, an interleukin -6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious respiratory complications.

Clinical combination of IDE196, a PKC inhibitor, and binimetinib, a MEK inhibitor, to be investigated in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer

ASLAN Pharmaceuticals reported financial results for the quarter and full year ended 31 December 2019 and provided an update on its clinical activities.

Data to be shared as a late-breaking oral presentation during the live virtual NKF conference

Golden Meditech Holdings Limited, a leading integrated healthcare enterprise in China, announced that its associate, Cellenkos, Inc. has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority to start a Phase 1/2 clinical trial with CK0802 for treatment of COVID-19 mediated acute respiratory distress syndrome.

Registration Now Open for LA-Area Event Dedicated to Raising Awareness of Neuropathy [18-March-2020] LOS ANGELES , March 18, 2020 /PRNewswire/ -- The Neuropathy Action Foundation (NAF) announced that registration is now open for its 13 th “Neuropathy Action Awareness Day,” an all-day educational event on June 19 in Los Angeles (Note: The NAF will evaluate the cor

Emergent BioSolutions Inc. announced that it has entered into an agreement with Vaxart, Inc., a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease.

Bio-Techne Corporation announced that the General Services Administration has awarded an unlimited 10-year reimbursement contract to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate test for men.